We are live on ! Find out more

Diagnostics & Research
Stocks Ranked by
Market Capitalization

Name Market cap Price Price
change %
TMO icon
1
Thermo Fisher Scientific
TMO
$260B
$260B $702.05 1.3%
DHR icon
2
Danaher
DHR
$165B
$165B $234.41 1.04%
NTRA icon
3
Natera
NTRA
$62.1B
$62.1B $430.81 4.87%
A icon
4
Agilent Technologies
A
$51.1B
$51.1B $181.12 2.05%
WAT icon
5
Waters Corp
WAT
$47B
$47B $478.49 2.12%
IQV icon
6
IQVIA
IQV
$45.5B
$45.5B $275.81 1.57%
IDXX icon
7
Idexx Laboratories
IDXX
$44.5B
$44.5B $564.33 0.55%
ILMN icon
8
Illumina
ILMN
$43.5B
$43.5B $287.77 2.97%
MTD icon
9
Mettler-Toledo International
MTD
$34.2B
$34.2B $1,705.63 1.21%
LH icon
10
Labcorp
LH
$29.6B
$29.6B $364.37 10%
DGX icon
11
Quest Diagnostics
DGX
$27B
$27B $244.66 0.87%
GH icon
12
Guardant Health
GH
$24.8B
$24.8B $184.98 3.89%
MEDP icon
13
Medpace
MEDP
$19.1B
$19.1B $683.79 1.48%
RVTY icon
14
Revvity
RVTY
$18.5B
$18.5B $165.43 2.21%
CRL icon
15
Charles River Laboratories
CRL
$17.8B
$17.8B $373.11 3.98%
ICLR icon
16
Icon
ICLR
$15.7B
$15.7B $203.42 11.2%
QGEN icon
17
Qiagen
QGEN
$10.4B
$10.4B $50.27 0.2%
GRAL icon
18
GRAIL Inc
GRAL
$7.12B
$7.12B $159.46 5.88%
RDNT icon
19
RadNet
RDNT
$5.86B
$5.86B $74.49 1.29%
BLLN icon
20
BillionToOne Inc
BLLN
$5.45B
$5.45B $115.51 1.26%
SHC icon
21
Sotera Health
SHC
$5.27B
$5.27B $18.47 0.11%
ADPT icon
22
Adaptive Biotechnologies
ADPT
$4.55B
$4.55B $28.51 3.07%
VCYT icon
23
Veracyte
VCYT
$4.07B
$4.07B $50.64 0.72%
CDNA icon
24
CareDx
CDNA
$3.74B
$3.74B $72.21 2.38%
NEO icon
25
NeoGenomics
NEO
$2.27B
$2.27B $17.69 2.43%
1
2

Diagnostics & Research Stocks at a Glance

Diagnostics and research companies run laboratory testing, imaging, and analytical services, and supply the instruments behind them. Testing volumes are recurring and largely non-discretionary, while research-tools demand follows pharma and academic R&D budgets.

There are 46 Diagnostics & Research industry stocks tracked by Wall St. Rank, worth a combined $963B.

The largest by market cap are Thermo Fisher Scientific (TMO) at $260B, Danaher (DHR) at $165B and Natera (NTRA) at $62.1B.

Among institutional investors, Guardant Health (GH) drew the most net new fund positions in Q2 2026: 161 funds opened new positions, taking total fund holders up 116 (24%) quarter-over-quarter.

Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q2 2026.